Form 4: Protalix Director Acquires Shares & Options

Protalix BioTherapeutics Director Amos Bar-Shalev reported the acquisition of 7,500 restricted common shares and 15,000 stock options.

Summary

• Amos Bar-Shalev, a Director of Protalix BioTherapeutics, Inc. (PLX), acquired 7,500 restricted shares of common stock on September 3, 2025.
• The restricted shares were awarded under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan and will vest in 12 equal quarterly installments starting from the grant date.
• Mr. Bar-Shalev also acquired 15,000 stock options with an exercise price of $1.64 per share on September 3, 2025.
• These stock options will vest in 12 equal quarterly installments commencing upon the date of grant and have an expiration date of September 3, 2035.
• The restricted shares are held indirectly by a trust to qualify for tax benefits under Section 102 of the Israeli Tax Ordinance.
• Existing option holdings not included in this report are 40,000 options at $3.55 (expiring Jan 20, 2030), 50,000 options at $1.03 (expiring Sep 7, 2032), and 61,676 options at $1.66 (expiring Sep 29, 2033).

Sentiment

Score: 7

Explanation: The acquisition of equity awards by a director is generally viewed as a positive signal, indicating alignment of interests with shareholders and confidence in the company's future. While not an open market purchase, it is a standard form of compensation that incentivizes long-term performance.

Positives

• The acquisition of restricted shares and stock options by a director aligns management's interests with those of shareholders, indicating continued commitment to the company's performance.
• Equity awards are a standard component of executive compensation, designed to incentivize long-term value creation.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transactions.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity compensation, common across all industries for publicly traded companies. It reflects standard corporate governance practices for incentivizing directors and executives through equity awards.

Corporate Governance

Related Party Transactions

• The acquisition of restricted shares and stock options by Director Amos Bar-Shalev constitutes a related party transaction, as it involves compensation provided to a member of the company's board of directors under an approved equity incentive plan.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with the company's long-term performance, potentially benefiting shareholders through incentivized value creation.
• Employees: The use of an equity incentive plan for directors may set a precedent or reflect a broader compensation philosophy that could extend to other key personnel.

Next Steps

• The restricted shares and stock options will vest in 12 equal quarterly installments, subject to the terms of the 2006 Stock Incentive Plan.

Key Dates

Recommendation

The filing reports routine equity compensation for a director, which is a standard practice to align management interests with shareholders. While a positive signal of continued commitment, it does not provide new fundamental information or a significant change in the company's outlook to warrant a 'buy' or 'sell' recommendation based solely on this transaction. Therefore, a 'hold' recommendation is appropriate.

Keywords

Protalix BioTherapeutics, PLX, Amos Bar-Shalev, Form 4, Insider Transaction, Stock Options, Restricted Stock, Director Compensation, Equity Award